We performed a prospective, observational, cohort study of children newly diagnosed with children's interstitial lung disease (ChILD), with structured follow-up at 4, 8, 12 weeks and 6 and 12 months. 127 children, median age 0.9 (IQR 0.3-7.9) years had dyspnoea (68%, 69/102), tachypnoea (75%, 77/103) and low oxygen saturation (SpO2) median 92% (IQR 88-96). Death (n=20, 16%) was the most common in those <6 months of age with SpO2<94% and developmental/surfactant disorders. We report for the first time that ChILD survivors improved multiple clinical parameters within 8-12 weeks of diagnosis. These data can inform family discussions and support clinical trial measurements.
- Cunningham, S.
- Graham, C.
- MacLean, M.
- Aurora, P.
- Ashworth, M.
- Barbato, A.
- Calder, A.
- Carlens, J.
- Clement, A.
- Hengst, M.
- Kammer, B.
- Kiper, N.
- Krenke, K.
- Kronfeld, K.
- Lange, J.
- Ley-Zaporozhan, J.
- Nicholson, A. G.
- Reu, S.
- Wesselak, T.
- Wetzke, M.
- Bush, A.
- Schwerk, N.
- Griese, M.
- Ch, Ildeu study group
Keywords
- Adolescent
- Adrenal Cortex Hormones/*administration & dosage
- Azithromycin/*administration & dosage
- Cause of Death
- Child
- Child, Preschool
- Cohort Studies
- Drug Therapy, Combination
- Europe
- Female
- Follow-Up Studies
- Humans
- Hydroxychloroquine/*administration & dosage
- Infant
- Kaplan-Meier Estimate
- Longitudinal Studies
- Lung Diseases, Interstitial/*diagnosis/*drug therapy/epidemiology
- Male
- Monitoring, Physiologic/methods
- Prospective Studies
- Registries
- Respiratory Function Tests
- Risk Assessment
- Severity of Illness Index
- Survival Analysis
- Time Factors
- *Interstitial lung disease in Children
- *mortality
- *oxygen saturation
- *ventilation
- the submitted work
- MG reports other from Vertex and Boehringer Ingelheim,
- outside the submitted work.
